BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trikafta (Elexacaftor / tezacaftor / ivacaftor) readouts · As
 setMemo
X-WR-CALDESC:Upcoming readouts of Trikafta (Elexacaftor / tezacaftor / ivac
 aftor)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05331183-10838@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 3 readout es
 t. (NCT05331183)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 3\, Cys
 tic Fibrosis.\nStudy: Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (
 ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del\nEs
 timated primary completion: 6 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05331183
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283770-10838@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 1 readout es
 t. (NCT07283770)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 1\, Cys
 tic Fibrosis.\nStudy: Evaluation of VX-581 in Healthy Participants and in 
 Participants With Cystic Fibrosis\nEstimated primary completion: 12 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/elexacaftor-teza
 caftor-ivacaftor#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07283770
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06460506-10838@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 3 readout es
 t. (NCT06460506)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 3\, Cys
 tic Fibrosis.\nStudy: Evaluation of Long-term Safety and Efficacy of ELX/T
 EZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06460506
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04602468-10838@assetmemo.bio
DTSTAMP:20261121T010454Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Trikafta (Elexacaftor / tezacaftor / ivacaftor): Phase 4 readout es
 t. (NCT04602468)
DESCRIPTION:Trikafta (Elexacaftor / tezacaftor / ivacaftor)\, phase 4\, Cys
 tic Fibrosis.\nStudy: Real World Clinical Outcomes With Novel Modulator Th
 erapy Combinations in People With CF (RECOVER)\nEstimated primary completi
 on: 1 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elex
 acaftor-tezacaftor-ivacaftor#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04602468
URL:https://assetmemo.bio/drug/elexacaftor-tezacaftor-ivacaftor#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
